Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420615 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00420615 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 34 participants.
The verdict
NCT00420615, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential inhibitory effects of patupilone on metabolism using midazolam and omeprazole as the respective probe drugs.
Interventions
- DRUG Patupilone and Omeprazole
- DRUG Patupilone + Midalzolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2006-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00420615
The ClinicalTrials.gov registry entry for NCT00420615 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Patupilone and Omeprazole is the first listed.
NCT00420615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00420615 about?
NCT00420615 is a clinical study titled "Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies". The purpose of this study is to evaluate the potential inhibitory effects of patupilone on metabolism using midazolam and omeprazole as the respective probe drugs.
What is the current status of trial NCT00420615?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2006-12.
What interventions are being tested in trial NCT00420615?
The interventions under investigation include: Patupilone and Omeprazole (DRUG), Patupilone + Midalzolam (DRUG).
Who is sponsoring clinical trial NCT00420615?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.